145903-06-6 Usage
Uses
Used in Pharmaceutical Industry:
4-[3-(4-Benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine is used as a potential therapeutic agent for the development of medications targeting the central nervous system. Its potential as a calcium channel blocker makes it a candidate for treating conditions related to abnormal calcium signaling, such as certain cardiovascular diseases or neurological disorders.
Additionally, due to its psychoactive properties, it may be utilized in the development of drugs for the treatment of psychiatric disorders, where modulation of neurotransmission could be beneficial.
Used in Research and Development:
In the scientific community, 4-[3-(4-Benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine serves as a valuable compound for research into the structure-activity relationships of benzothiazepine drugs. It aids in understanding how modifications to the molecular structure can influence pharmacological activity, potentially leading to the discovery of new drugs with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 145903-06-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,5,9,0 and 3 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 145903-06:
(8*1)+(7*4)+(6*5)+(5*9)+(4*0)+(3*3)+(2*0)+(1*6)=126
126 % 10 = 6
So 145903-06-6 is a valid CAS Registry Number.
145903-06-6Relevant articles and documents
Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
-
Page/Page column 37, (2008/06/13)
The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.
